Potential factors for prediction of Stable MR4.5 during imatinib therapy for up to 8 years
| Variable . | . | Stable MR4.5 (%) . | Relative risk (95% CI) . | Overall P value . |
|---|---|---|---|---|
| Median age (y) | ||||
| ≤48 | 37.3 | 1 | .67 | |
| >48 | 35.9 | 1.11 (0.67-1.85) | ||
| Sex, n (%) | ||||
| Male | 240 (57) | 27.2 | 1 | <.001 |
| Female | 183 (43) | 54.4 | 2.51 (1.52-4.15) | |
| Sokal risk group, n (%)* | ||||
| High | 116 (29) | 21.5 | 1 | .081 |
| Intermediate | 129 (32) | 38.7 | 1.64 (0.73-3.67) | |
| Low | 162 (40) | 45.3 | 2.26 (1.09-4.71) | |
| Assigned imatinib dose, n (%) | ||||
| 400 mg | 91 (22) | 33.7 | 1 | .49 |
| 600 mg | 208 (49) | 35.6 | 1.43 (0.76-2.68) | |
| 800 mg | 124 (29) | >36.8 | 1.44 (0.69-3.00) | |
| 3-mo BCR-ABL1IS, n (%)† | ||||
| ≤0.10% | 38 (9.2) | 78.2 | 1 | <.001 |
| >0.10%-1% | 147 (36) | 52.7 | 0.29 (0.15-0.58) | |
| >1%-10% | 144 (35) | 29.0 | 0.12 (0.06-0.24) | |
| >10% | 84 (21) | 8.6 | 0.02 (0.002-0.13) |
| Variable . | . | Stable MR4.5 (%) . | Relative risk (95% CI) . | Overall P value . |
|---|---|---|---|---|
| Median age (y) | ||||
| ≤48 | 37.3 | 1 | .67 | |
| >48 | 35.9 | 1.11 (0.67-1.85) | ||
| Sex, n (%) | ||||
| Male | 240 (57) | 27.2 | 1 | <.001 |
| Female | 183 (43) | 54.4 | 2.51 (1.52-4.15) | |
| Sokal risk group, n (%)* | ||||
| High | 116 (29) | 21.5 | 1 | .081 |
| Intermediate | 129 (32) | 38.7 | 1.64 (0.73-3.67) | |
| Low | 162 (40) | 45.3 | 2.26 (1.09-4.71) | |
| Assigned imatinib dose, n (%) | ||||
| 400 mg | 91 (22) | 33.7 | 1 | .49 |
| 600 mg | 208 (49) | 35.6 | 1.43 (0.76-2.68) | |
| 800 mg | 124 (29) | >36.8 | 1.44 (0.69-3.00) | |
| 3-mo BCR-ABL1IS, n (%)† | ||||
| ≤0.10% | 38 (9.2) | 78.2 | 1 | <.001 |
| >0.10%-1% | 147 (36) | 52.7 | 0.29 (0.15-0.58) | |
| >1%-10% | 144 (35) | 29.0 | 0.12 (0.06-0.24) | |
| >10% | 84 (21) | 8.6 | 0.02 (0.002-0.13) |